Accuray approves 1-for-40 reverse stock split effective Nov. 9
Accuray Inc. (NASDAQ:ARAY) approved a 1-for-40 reverse stock split, effective Nov. 9, 2026. The split aims to boost the stock price and comply with Nasdaq's minimum bid price requirement. Outstanding shares will reduce from 120.2M to 3M, with no fractional shares issued. Computershare Trust Company is the exchange agent.
How this was made
The 30-second read
Why it matters
The split restores Nasdaq compliance, may improve liquidity, and could attract institutional investors who avoid sub‑$1 stocks.
Market read
A corporate action that could modestly affect ARAY's price and compliance status, with limited broader market impact.
What to watch
Potential dilution from future equity incentives and the cash payment for fractional shares could offset price gains.
Background
Accuray is a medical device maker focused on radiation therapy solutions. The reverse split is intended to meet Nasdaq's $1 minimum bid price rule.
Ticker impact
Accuray announced a 1‑for‑40 reverse stock split to regain Nasdaq minimum price compliance.
potential modest upside as the market prices in compliance restoration
Reverse splits are typically viewed as a compliance move; they do not change fundamentals but can lift the stock above the $1 threshold, attracting investors who avoid sub‑$1 stocks.
Market effects
May prompt other low‑price med‑tech stocks to consider similar actions to stay listed.
Limited to US Nasdaq‑listed med‑tech sector.
Minimal; primarily a company‑specific compliance move.
Counterpoint
Some investors may view the split as a red flag, fearing underlying weakness and may short the stock.
Key entities
- companyAccuray Incorporated
Medical device company executing the reverse split.
- service_providerComputershare Trust Company, N.A.
Exchange agent handling the split.
